Get the Stockscreener App
10.82
5.34%
-0.61
Ginkgo Bioworks Holdings Inc stock is traded at $10.82, with a volume of 2.02M.
It is down -5.34% in the last 24 hours and down -6.56% over the past month.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering and BiosecurityThe majority of revenue in the company comes from the Biosecurity segment, which charges fees for data analytics and services.
See More
Previous Close:
$11.43
Open:
$11.7
24h Volume:
2.02M
Relative Volume:
1.30
Market Cap:
$621.92M
Revenue:
$217.11M
Net Income/Loss:
$-651.19M
P/E Ratio:
-0.8329
EPS:
-12.99
Net Cash Flow:
$-387.26M
1W Performance:
-26.54%
1M Performance:
-6.56%
6M Performance:
+16.22%
1Y Performance:
-79.03%
1-Day Range:
$10.81
$12.26
1-Week Range:
$10.81
$15.96
52-Week Range:
$5.26
$64.40
Ginkgo Bioworks Holdings Inc Stock (DNA) Company Profile
Name
Ginkgo Bioworks Holdings Inc
Sector
Industry
Phone
(877) 442-5362
Address
27 DRYDOCK AVENUE, BOSTON
Compare DNA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DNA
Ginkgo Bioworks Holdings Inc
|
10.82 | 621.92M | 217.11M | -651.19M | -387.26M | -12.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Ginkgo Bioworks Holdings Inc Stock (DNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-15-24 | Downgrade | BTIG Research | Neutral → Sell |
| May-10-24 | Downgrade | William Blair | Mkt Perform → Underperform |
| Nov-14-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-09-23 | Downgrade | BTIG Research | Buy → Neutral |
| Jun-02-23 | Downgrade | Goldman | Neutral → Sell |
| May-11-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Nov-29-22 | Initiated | Berenberg | Buy |
| Oct-04-22 | Initiated | Morgan Stanley | Equal-Weight |
| May-18-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Mar-02-22 | Resumed | Cowen | Outperform |
| Feb-23-22 | Initiated | Goldman | Neutral |
| Feb-01-22 | Initiated | BofA Securities | Neutral |
| Jan-28-22 | Initiated | BofA Securities | Buy |
| Jan-07-22 | Initiated | BTIG Research | Buy |
| Nov-29-21 | Initiated | Jefferies | Buy |
| Oct-13-21 | Initiated | Raymond James | Outperform |
| Oct-12-21 | Initiated | William Blair | Outperform |
| Sep-20-21 | Initiated | HSBC Securities | Buy |
View All
Ginkgo Bioworks Holdings Inc Stock (DNA) Latest News
Volta Labs enhances Ginkgo Bioworks sequencing workflow By Investing.com - Investing.com Canada
Ginkgo Bioworks Integrates Callisto For Difficult-To-Automate Ngs Processes In Their High-Throughput Lab - Marketscreener.com
Ginkgo Bioworks integrates Callisto for difficult-to-automate NGS processes in their high-throughput lab - Marketscreener.com
Can This New Lab Automation System Transform Ginkgo's DNA Sequencing Capabilities? - StockTitan
Short Interest in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Rises By 5.4% - MarketBeat
Ginkgo Bioworks (DNA) to Release Earnings on Tuesday - MarketBeat
Ginkgo Bioworks Partners With HaDEA on Up to $25.1 Million Project for Rapid Virus Diagnostics - Marketscreener.com
Ginkgo Bioworks Partners with HaDEA in Up to €24 Million Consortium Project to Deliver Next-Generation 'Agnostic Diagnostics' for Respiratory Viruses at the Point of Care - PR Newswire
Ginkgo Bioworks (NYSE:DNA) Shares Down 6.3%Time to Sell? - MarketBeat
Ginkgo Bioworks Holdings, Inc. (DNA) Dips More Than Broader Market: What You Should Know - MSN
Ginkgo Bioworks Announces Date of Fourth Quarter and Full Year 2024 Results Presentation - BioSpace
Ginkgo Bioworks Sets Stage for Crucial Q4 Earnings: Here's When to Tune In - StockTitan
Ginkgo Bioworks (NYSE:DNA) Trading 8.8% HigherStill a Buy? - MarketBeat
Ginkgo Bioworks (NYSE:DNA) Shares Down 5.4%Here's What Happened - MarketBeat
DNAGinkgo Bioworks to Host 6th Annual Ferment as Boston-based Conference Series - ADVFN
Ginkgo Bioworks Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 - Marketscreener.com
Revenues Not Telling The Story For Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) After Shares Rise 39% - Simply Wall St
SG Americas Securities LLC Purchases New Stake in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) - MarketBeat
(DNA) Technical Pivots with Risk Controls - Stock Traders Daily
Ginkgo Bioworks (NYSE:DNA) Trading Up 7.9%What's Next? - MarketBeat
Ginkgo Bioworks CFO Dmytruk sells $9,947 in stock - MSN
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Shares Purchased by Forbes J M & Co. LLP - MarketBeat
Ginko Automation to deploy flexible laboratory automation system at GLBRC - Biodiesel Magazine
Ginkgo Bioworks (NYSE:DNA) Trading Down 6.8%Should You Sell? - MarketBeat
Ginkgo Bioworks (NYSE:DNA) Shares Up 7.9%Here's Why - MarketBeat
Ginkgo Bioworks' chief accounting officer sells $4,933 in stock - MSN
Strength Seen in Ginkgo Bioworks (DNA): Can Its 14.5% Jump Turn into More Strength? - MSN
Ginkgo Bioworks (NYSE:DNA) Shares Gap DownShould You Sell? - MarketBeat
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Shares Sold by JPMorgan Chase & Co. - MarketBeat
Ginkgo Bioworks (DNA) Upgraded to Strong Buy: Here's What You Should Know - MSN
Ginkgo Bioworks' chief accounting officer sells $4,933 in stock By Investing.com - Investing.com Canada
Ginkgo Bioworks CFO Dmytruk sells $9,947 in stock By Investing.com - Investing.com South Africa
Ginkgo Bioworks to Host 6th Annual Ferment as Boston-based Conference Series - Quantisnow
PFG Investments LLC Sells 170,130 Shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) - MarketBeat
Ginkgo Bioworks (NYSE:DNA) Stock Price Down 6.3%Time to Sell? - MarketBeat
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Position Trimmed by JPMorgan Chase & Co. - Defense World
Ginkgo Bioworks (NYSE:DNA) Shares Up 9.7%What's Next? - MarketBeat
Ginkgo Bioworks Holdings Inc Stock (DNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.27%
3.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):